Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase

Georgios Pantouris, Christopher G. Mowat*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The involvement of tryptophan 2,3-dioxygenase (TDO) in cancer biology has recently been described, with the enzyme playing an immunomodulatory role, suppressing antitumour immune responses and promoting tumour cell survival and proliferation. This finding reinforces the need for specific inhibitors of TDO that may potentially be developed for therapeutic use. In this work we have screened ∼2800 compounds from the library of the National Cancer Institute USA and identified seven potent inhibitors of TDO with inhibition constants in the nanomolar or low micromolar range. All seven have antitumour properties, killing various cancer cell lines. For comparison, the inhibition potencies of these compounds were tested against IDO and their inhibition constants are reported. Interestingly, this work reveals that NSC 36398 (dihydroquercetin, taxifolin), with an in vitro inhibition constant of ∼16 μM, is the first TDO-selective inhibitor reported.

Original languageEnglish
Pages (from-to)28-31
Number of pages4
JournalBiochemical and Biophysical Research Communications
Volume443
Issue number1
Early online date19 Nov 2013
DOIs
Publication statusPublished - 3 Jan 2014

Keywords

  • Tryptophan 2,3-dioxygenase
  • Cancer
  • Kynurenine pathway
  • BETA-LAPACHONE
  • INDOLEAMINE 2,3-DIOXYGENASE
  • CANCER-CELLS
  • APOPTOSIS
  • ENZYMES
  • EXPRESSION
  • RESISTANCE
  • INDUCTION
  • MECHANISM
  • THERAPY

Fingerprint

Dive into the research topics of 'Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase'. Together they form a unique fingerprint.

Cite this